Healthcare entity

Ocular Therapeutix, Inc.

Company OCUL

Every one of those 1 sits in a single category, market-trends. Ocular Therapeutix, Inc. is most often covered alongside Bayer Aktiengesellschaft, which appears in 1 of these 1 story. Each story carries 54 original sources on average, compared with 6 for the broader beat in this window.

Last mentioned: Feb 20, 2026

Entity pulse

Recent coverage · Ocular Therapeutix, Inc.

1 story
7 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Ocular Therapeutix, Inc.

Every one of those 1 sits in a single category, market-trends. Ocular Therapeutix, Inc. is most often covered alongside Bayer Aktiengesellschaft, which appears in 1 of these 1 story. Each story carries 54 original sources on average, compared with 6 for the broader beat in this window. At 7, the average consequence score sits above the same-window beat average of 5.8. Ocular Therapeutix, Inc. appears in 1 tracked Healthcare story from February 20, 2026.

Stories tracked
1
Sources per story
54

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Ocular Therapeutix, Inc.. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning Ocular Therapeutix, Inc. 1

Market Trends Strongly positive

Biotech Volatility: Genmab Profits Slide as Clinical Wins Drive Market Divergence

A wave of earnings reports and clinical trial results has triggered significant volatility across the healthcare and biotech sectors. While Genmab reported a decline in full-year profits, breakthrough Phase 3 results from Compass Pathways and Ocular Therapeutix highlight a sharp divergence between clinical success and market valuation.

54 sources

Source: Rttnews · Rttnews

Ocular Therapeutix, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.